Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 280

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 280
---
 2000 to November 2004, he served as Audit Manager at EY. Mr.Twito is a Certified Public Accountant (CPA) in Israel and holds a bachelor’s degree in Business Administration and Accounting from the College of Management Academic Studies, Israel. He maintains active membership in the Institute of Certified Public Accountants in Israel. Prof. Michel Revel, MD, PhD, Chief Scientific Officer and Director Prof. Michel Revel, MD, PhD, has served as Chief Scientific Officer of Kadimastem and board member since 2010, and is Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. In January 1968, he was appointed as Senior Scientist of the Department of Biochemistry at the Weizmann Institute of Science in Rehovot, Israel, where he has been a full -timeProfessor since January 1973, heading for several periods the Departments of Virology and of Molecular Genetics. His research on Interferon, its mechanisms of action and the isolation of the human Interferon -betagene, has led to the development of Interferon -betatherapy for the treatment of multiple sclerosis, Rebif®, a Blockbuster drug marketed worldwide which was later sold to Merck Serono. In recent years, Prof. Revel’s laboratory has focused on hESC and has succeeded in producing nerve myelinating cells that, when transplanted in myelin -deficientanimals, have regenerated the myelin coating. These studies contributed to the development of a suspension culture technology for hESC which can then be used to produce differentiated human cells such as insulin -producingpancreatic beta cells and nerve myelinating cells. Alongside his research and development activity, Prof. Revel is deeply involved in the ethics of science and biotechnology, and served as Chairman of the Israel National Bioethics Council and was a member of the International Bioethics Committee of UNESCO. Prof. Revel was the recipient of the Israel Prize for medical research, the EMET Prize for biotechnology, and is a member of the Israel Academy of Science and Humanities. He has been a member of Israel’s National Committee for Biotechnology, serving for three years as its Chairman. Professor Revel holds M.D. and Ph.D. degrees from the University of Strasbourg, France. 118 Eran Iohan, Independent Director Mr.Eran Iohan has served as a director of Kadimastem since October of 2022. Mr.Iohan brings with him over 20 years of